Smith & Nephew: are shares in this FTSE 100 company a buy?
More on: Image source: Getty Images.
The medical device industry – often seen as the poor relation of the pharmaceuticals and healthcare space – suffered in 2020. Elective routine surgical procedures took a back seat for most of last year, but now that the Covid-19 vaccine programme is gaining pace, things are looking up for one FTSE 100 company.
The share price for
Smith & Nephew(LSE: SN) has grown 15% over the last six weeks alone, and still has some way to go, if its pre-pandemic stock valuation is anything to go by. This, together with the fact that the company has never yet failed to pay out a dividend since it was first listed back in the 1930s, leads me to give it serious consideration as an addition to my investment portfolio.